221 related articles for article (PubMed ID: 17441705)
1. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.
Feng J; Zhang Z; Wallace MB; Stafford JA; Kaldor SW; Kassel DB; Navre M; Shi L; Skene RJ; Asakawa T; Takeuchi K; Xu R; Webb DR; Gwaltney SL
J Med Chem; 2007 May; 50(10):2297-300. PubMed ID: 17441705
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
[TBL] [Abstract][Full Text] [Related]
3. Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin.
Agrawal R; Bahare RS; Jain P; Dikshit SN; Ganguly S
Mini Rev Med Chem; 2012 Nov; 12(13):1345-58. PubMed ID: 22512582
[TBL] [Abstract][Full Text] [Related]
4. Design and Discovery of Novel 1,3,5-Triazines as Dipeptidyl Peptidase-4 Inhibitor against Diabetes.
Wang Y; Tang X; Yi L
Pharmacology; 2019; 103(5-6):273-281. PubMed ID: 30799431
[TBL] [Abstract][Full Text] [Related]
5. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Deacon CF
Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
[TBL] [Abstract][Full Text] [Related]
6. Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.
Nishio Y; Kimura H; Tosaki S; Sugaru E; Sakai M; Horiguchi M; Masui Y; Ono M; Nakagawa T; Nakahira H
Bioorg Med Chem Lett; 2010 Dec; 20(24):7246-9. PubMed ID: 21074430
[TBL] [Abstract][Full Text] [Related]
7. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.
Eckhardt M; Langkopf E; Mark M; Tadayyon M; Thomas L; Nar H; Pfrengle W; Guth B; Lotz R; Sieger P; Fuchs H; Himmelsbach F
J Med Chem; 2007 Dec; 50(26):6450-3. PubMed ID: 18052023
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel pyrazolo-pyrimidinones as DPP-IV inhibitors in diabetes.
Sagar SR; Agarwal JK; Pandya DH; Dash RP; Nivsarkar M; Vasu KK
Bioorg Med Chem Lett; 2015 Oct; 25(20):4428-33. PubMed ID: 26372650
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.
Zhang Z; Wallace MB; Feng J; Stafford JA; Skene RJ; Shi L; Lee B; Aertgeerts K; Jennings A; Xu R; Kassel DB; Kaldor SW; Navre M; Webb DR; Gwaltney SL
J Med Chem; 2011 Jan; 54(2):510-24. PubMed ID: 21186796
[TBL] [Abstract][Full Text] [Related]
10. Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin.
Lai ZW; Li C; Liu J; Kong L; Wen X; Sun H
Eur J Med Chem; 2014 Aug; 83():547-60. PubMed ID: 24996141
[TBL] [Abstract][Full Text] [Related]
11. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
Asakawa T; Moritoh Y; Kataoka O; Suzuki N; Takeuchi K; Odaka H
Life Sci; 2009 Jul; 85(3-4):122-6. PubMed ID: 19427871
[TBL] [Abstract][Full Text] [Related]
12. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
Ndefo UA; Okoli O; Erowele G
Am J Health Syst Pharm; 2014 Jan; 71(2):103-9. PubMed ID: 24375601
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.
Meng W; Brigance RP; Chao HJ; Fura A; Harrity T; Marcinkeviciene J; O'Connor SP; Tamura JK; Xie D; Zhang Y; Klei HE; Kish K; Weigelt CA; Turdi H; Wang A; Zahler R; Kirby MS; Hamann LG
J Med Chem; 2010 Aug; 53(15):5620-8. PubMed ID: 20684603
[TBL] [Abstract][Full Text] [Related]
14. Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice.
Nonogaki K; Kaji T
Diabetes Res Clin Pract; 2015 Dec; 110(3):e18-21. PubMed ID: 26497774
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors.
Li N; Wang LJ; Jiang B; Guo SJ; Li XQ; Chen XC; Luo J; Li C; Wang Y; Shi DY
Bioorg Med Chem Lett; 2018 Jul; 28(12):2131-2135. PubMed ID: 29773502
[TBL] [Abstract][Full Text] [Related]
16. Alogliptin benzoate for the treatment of type 2 diabetes.
Rendell M; Drincic A; Andukuri R
Expert Opin Pharmacother; 2012 Mar; 13(4):553-63. PubMed ID: 22296609
[TBL] [Abstract][Full Text] [Related]
17. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1225-38. PubMed ID: 26218204
[TBL] [Abstract][Full Text] [Related]
18. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
19. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors.
Deng X; Han L; Zhou J; Zhang H; Li Q
Bioorg Chem; 2017 Dec; 75():357-367. PubMed ID: 29096096
[TBL] [Abstract][Full Text] [Related]
20. Optimization of the benzamide fragment targeting the S
Deng X; Wang N; Meng L; Zhou S; Huang J; Xing J; He L; Jiang W; Li Q
Bioorg Chem; 2020 Jan; 94():103366. PubMed ID: 31640932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
